Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Inhibition of discoidin domain receptor 1 prevents stroma-induced peritoneal metastasis in gastric carcinoma.

Jin H, Ham IH, Oh HJ, Bae CA, Lee DK, Kim YB, Son SY, Chwae YJ, Han SU, Brekken RA, Hur H.

Mol Cancer Res. 2018 Jun 4. pii: molcanres.0710.2017. doi: 10.1158/1541-7786.MCR-17-0710. [Epub ahead of print]

PMID:
29866925
2.

Author Correction: Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan.

Wang C, Niederstrasser H, Douglas PM, Lin R, Jaramillo J, Li Y, Oswald NW, Zhou A, McMillan EA, Mendiratta S, Wang Z, Zhao T, Lin Z, Luo M, Huang G, Brekken RA, Posner BA, MacMillan JB, Gao J, White MA.

Nat Commun. 2018 May 21;9(1):2050. doi: 10.1038/s41467-018-04519-8.

3.

Exploration of Nanoparticle-Mediated Photothermal Effect of TMB-H2O2 Colorimetric System and Its Application in a Visual Quantitative Photothermal Immunoassay.

Fu G, Sanjay ST, Zhou W, Brekken RA, Kirken RA, Li X.

Anal Chem. 2018 May 1;90(9):5930-5937. doi: 10.1021/acs.analchem.8b00842. Epub 2018 Apr 17.

PMID:
29641893
4.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE.

Oncotarget. 2017 Dec 31;9(6):6659-6677. doi: 10.18632/oncotarget.23795. eCollection 2018 Jan 23.

5.

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.

Belzile O, Huang X, Gong J, Carlson J, Schroit AJ, Brekken RA, Freimark BD.

Immunotargets Ther. 2018 Jan 23;7:1-14. doi: 10.2147/ITT.S134834. eCollection 2018. Review.

6.

Manually Steerable Catheter With Improved Agility.

Tangen GA, Manstad-Hulaas F, Nypan E, Brekken R.

Clin Med Insights Cardiol. 2018 Jan 4;12:1179546817751432. doi: 10.1177/1179546817751432. eCollection 2018.

7.

Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan.

Wang C, Niederstrasser H, Douglas PM, Lin R, Jaramillo J, Li Y, Oswald NW, Zhou A, McMillan EA, Mendiratta S, Wang Z, Zhao T, Lin Z, Luo M, Huang G, Brekken RA, Posner BA, MacMillan JB, Gao J, White MA.

Nat Commun. 2017 Dec 22;8(1):2270. doi: 10.1038/s41467-017-02332-3. Erratum in: Nat Commun. 2018 May 21;9(1):2050.

8.

Assessment of TANK-binding kinase 1 as a therapeutic target in cancer.

Cruz VH, Brekken RA.

J Cell Commun Signal. 2018 Mar;12(1):83-90. doi: 10.1007/s12079-017-0438-y. Epub 2017 Dec 7. Review.

9.

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.

Ludwig KF, Du W, Sorrelle NB, Wnuk-Lipinska K, Topalovski M, Toombs JE, Cruz VH, Yabuuchi S, Rajeshkumar NV, Maitra A, Lorens JB, Brekken RA.

Cancer Res. 2018 Jan 1;78(1):246-255. doi: 10.1158/0008-5472.CAN-17-1973. Epub 2017 Nov 27.

PMID:
29180468
10.

Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor.

Wu X, Zhang LS, Toombs J, Kuo YC, Piazza JT, Tuladhar R, Barrett Q, Fan CW, Zhang X, Walensky LD, Kool M, Cheng SY, Brekken R, Opferman JT, Green DR, Moldoveanu T, Lum L.

Nat Cell Biol. 2017 Oct;19(10):1226-1236. doi: 10.1038/ncb3616. Epub 2017 Sep 25.

11.

Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Aguilera KY, Huang H, Du W, Hagopian MM, Wang Z, Hinz S, Hwang TH, Wang H, Fleming JB, Castrillon DH, Ren X, Ding K, Brekken RA.

Mol Cancer Ther. 2017 Nov;16(11):2473-2485. doi: 10.1158/1535-7163.MCT-16-0834. Epub 2017 Sep 1.

PMID:
28864681
12.

Extracellular Matrix Induction of Intracellular Reactive Oxygen Species.

Huang H, Du W, Brekken RA.

Antioxid Redox Signal. 2017 Oct 20;27(12):774-784. doi: 10.1089/ars.2017.7305. Review.

PMID:
28791881
13.

Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.

Sharma R, Huang X, Brekken RA, Schroit AJ.

Br J Cancer. 2017 Aug 8;117(4):545-552. doi: 10.1038/bjc.2017.183. Epub 2017 Jun 22.

PMID:
28641308
14.

A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis.

Xiang Z, Zhou ZJ, Xia GK, Zhang XH, Wei ZW, Zhu JT, Yu J, Chen W, He Y, Schwarz RE, Brekken RA, Awasthi N, Zhang CH.

Oncogene. 2017 Sep 7;36(36):5122-5133. doi: 10.1038/onc.2017.108. Epub 2017 May 8.

PMID:
28481874
15.

From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.

Sorrelle N, Dominguez ATA, Brekken RA.

J Leukoc Biol. 2017 Aug;102(2):277-286. doi: 10.1189/jlb.3MR1116-475R. Epub 2017 Mar 29. Review.

PMID:
28356350
16.

Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.

Wang Z, Zhang Y, Bartual SG, Luo J, Xu T, Du W, Xun Q, Tu Z, Brekken RA, Ren X, Bullock AN, Liang G, Lu X, Ding K.

ACS Med Chem Lett. 2017 Feb 9;8(3):327-332. doi: 10.1021/acsmedchemlett.6b00497. eCollection 2017 Mar 9.

17.

Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and β2AR-Dependent Neo-Angiogenic Switch.

Mulcrone PL, Campbell JP, Clément-Demange L, Anbinder AL, Merkel AR, Brekken RA, Sterling JA, Elefteriou F.

J Bone Miner Res. 2017 Jul;32(7):1442-1454. doi: 10.1002/jbmr.3133. Epub 2017 Apr 28.

PMID:
28300321
18.

Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma.

Hur H, Ham IH, Lee D, Jin H, Aguilera KY, Oh HJ, Han SU, Kwon JE, Kim YB, Ding K, Brekken RA.

BMC Cancer. 2017 Jan 31;17(1):87. doi: 10.1186/s12885-017-3051-9.

19.

Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.

Dai B, Roife D, Kang Y, Gumin J, Rios Perez MV, Li X, Pratt M, Brekken RA, Fueyo-Margareto J, Lang FF, Fleming JB.

Mol Cancer Ther. 2017 Apr;16(4):662-670. doi: 10.1158/1535-7163.MCT-16-0526. Epub 2017 Jan 30.

20.

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.

Tagal V, Wei S, Zhang W, Brekken RA, Posner BA, Peyton M, Girard L, Hwang T, Wheeler DA, Minna JD, White MA, Gazdar AF, Roth MG.

Nat Commun. 2017 Jan 19;8:14098. doi: 10.1038/ncomms14098.

21.

The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.

Wieczorek M, Tcherkezian J, Bernier C, Prota AE, Chaaban S, Rolland Y, Godbout C, Hancock MA, Arezzo JC, Ocal O, Rocha C, Olieric N, Hall A, Ding H, Bramoullé A, Annis MG, Zogopoulos G, Harran PG, Wilkie TM, Brekken RA, Siegel PM, Steinmetz MO, Shore GC, Brouhard GJ, Roulston A.

Sci Transl Med. 2016 Nov 16;8(365):365ra159. Erratum in: Sci Transl Med. 2017 Dec 20;9(421):.

22.

Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco.

Wojtukiewicz MZ, Sierko E, Skalij P, Kamińska M, Zimnoch L, Brekken RA, Thorpe PE.

Adv Clin Exp Med. 2016 May-Jun;25(3):505-11. doi: 10.17219/acem/62398.

23.

Hypoxia and Transforming Growth Factor β Cooperate to Induce Fibulin-5 Expression in Pancreatic Cancer.

Topalovski M, Hagopian M, Wang M, Brekken RA.

J Biol Chem. 2016 Oct 14;291(42):22244-22252. Epub 2016 Aug 16.

24.

Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.

Mineo C, Lanier L, Jung E, Sengupta S, Ulrich V, Sacharidou A, Tarango C, Osunbunmi O, Shen YM, Salmon JE, Brekken RA, Huang X, Thorpe PE, Shaul PW.

PLoS One. 2016 Jul 27;11(7):e0158757. doi: 10.1371/journal.pone.0158757. eCollection 2016.

25.

Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.

Díaz B, Ostapoff KT, Toombs JE, Lo J, Bonner MY, Curatolo A, Adsay V, Brekken RA, Arbiser JL.

Oncotarget. 2016 Aug 9;7(32):51569-51580. doi: 10.18632/oncotarget.10514.

26.

Stromal TGFβR2 signaling: a gateway to progression for pancreatic cancer.

Hagopian MM, Brekken RA.

Mol Cell Oncol. 2014 Dec 1;2(3):e975606. doi: 10.4161/23723556.2014.975606. eCollection 2015 Jul-Sep.

27.

Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy.

Zhang Z, Wodzak M, Belzile O, Zhou H, Sishc B, Yan H, Stojadinovic S, Mason RP, Brekken RA, Chopra R, Story MD, Timmerman R, Saha D.

Radiat Res. 2016 Jun;185(6):616-22. doi: 10.1667/RR14382.1. Epub 2016 May 25.

28.

Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.

Wang Z, Bian H, Bartual SG, Du W, Luo J, Zhao H, Zhang S, Mo C, Zhou Y, Xu Y, Tu Z, Ren X, Lu X, Brekken RA, Yao L, Bullock AN, Su J, Ding K.

J Med Chem. 2016 Jun 23;59(12):5911-6. doi: 10.1021/acs.jmedchem.6b00140. Epub 2016 Jun 3.

29.

Registration of Real-Time 3-D Ultrasound to Tomographic Images of the Abdominal Aorta.

Brekken R, Iversen DH, Tangen GA, Dahl T.

Ultrasound Med Biol. 2016 Aug;42(8):2026-32. doi: 10.1016/j.ultrasmedbio.2016.03.021. Epub 2016 May 5.

PMID:
27156015
30.

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.

Levin PA, Brekken RA, Byers LA, Heymach JV, Gerber DE.

J Thorac Oncol. 2016 Aug;11(8):1357-1362. doi: 10.1016/j.jtho.2016.04.015. Epub 2016 Apr 26. No abstract available.

31.

Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.

Desai TJ, Toombs JE, Minna JD, Brekken RA, Udugamasooriya DG.

Oncotarget. 2016 May 24;7(21):30678-90. doi: 10.18632/oncotarget.8929.

32.

Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.

Freimark BD, Gong J, Ye D, Gray MJ, Nguyen V, Yin S, Hatch MM, Hughes CC, Schroit AJ, Hutchins JT, Brekken RA, Huang X.

Cancer Immunol Res. 2016 Jun;4(6):531-40. doi: 10.1158/2326-6066.CIR-15-0250. Epub 2016 Apr 4.

33.

P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.

Goel HL, Pursell B, Shultz LD, Greiner DL, Brekken RA, Vander Kooi CW, Mercurio AM.

Cell Rep. 2016 Mar 8;14(9):2193-2208. doi: 10.1016/j.celrep.2016.02.016. Epub 2016 Feb 25.

34.

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer.

Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, Barcinski M, Brekken RA, Huang X, Hutchins JT, Freimark B, Empig C, Mercer J, Schroit AJ, Schett G, Herrmann M.

Cell Death Differ. 2016 Jun;23(6):962-78. doi: 10.1038/cdd.2016.11. Epub 2016 Feb 26. Review.

35.

Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.

Cheng X, Li L, Thorpe PE, Yopp AC, Brekken RA, Huang X.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. Epub 2016 Feb 4.

PMID:
26847681
36.

Pulsatile Dynamics of the Optic Nerve Sheath and Intracranial Pressure: An Exploratory In Vivo Investigation.

Padayachy L, Brekken R, Fieggen G, Selbekk T.

Neurosurgery. 2016 Jul;79(1):100-7. doi: 10.1227/NEU.0000000000001200.

37.

Matrix control of pancreatic cancer: New insights into fibronectin signaling.

Topalovski M, Brekken RA.

Cancer Lett. 2016 Oct 10;381(1):252-8. doi: 10.1016/j.canlet.2015.12.027. Epub 2015 Dec 29. Review.

38.

A Transistor-like pH Nanoprobe for Tumour Detection and Image-guided Surgery.

Zhao T, Huang G, Li Y, Yang S, Ramezani S, Lin Z, Wang Y, Ma X, Zeng Z, Luo M, de Boer E, Xie XJ, Thibodeaux J, Brekken RA, Sun X, Sumer BD, Gao J.

Nat Biomed Eng. 2016;1. pii: 0006. doi: 10.1038/s41551-016-0006. Epub 2016 Dec 19.

39.

The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.

Mastri M, Rosario S, Tracz A, Frink RE, Brekken RA, Ebos JM.

Curr Drug Targets. 2016;17(15):1747-1754. Review.

40.

Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer.

Wang M, Topalovski M, Toombs JE, Wright CM, Moore ZR, Boothman DA, Yanagisawa H, Wang H, Witkiewicz A, Castrillon DH, Brekken RA.

Cancer Res. 2015 Dec 1;75(23):5058-69. doi: 10.1158/0008-5472.CAN-15-0744. Epub 2015 Nov 17.

41.

Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.

Gerber DE, Hao G, Watkins L, Stafford JH, Anderson J, Holbein B, Öz OK, Mathews D, Thorpe PE, Hassan G, Kumar A, Brekken RA, Sun X.

Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):493-503. eCollection 2015.

42.

Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo.

Li T, Aredo B, Zhang K, Zhong X, Pulido JS, Wang S, He YG, Huang X, Brekken RA, Ufret-Vincenty RL.

Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7137-45. doi: 10.1167/iovs.15-17302.

43.

Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells.

Matharage JM, Minna JD, Brekken RA, Udugamasooriya DG.

ACS Chem Biol. 2015 Dec 18;10(12):2891-9. doi: 10.1021/acschembio.5b00592. Epub 2015 Oct 28.

44.

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.

Ocal O, Pashkov V, Kollipara RK, Zolghadri Y, Cruz VH, Hale MA, Heath BR, Artyukhin AB, Christie AL, Tsoulfas P, Lorens JB, Swift GH, Brekken RA, Wilkie TM.

Dis Model Mech. 2015 Oct 1;8(10):1201-11. doi: 10.1242/dmm.020933.

45.

LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.

Peña CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, Miller DS, Lea JS, Wong KK, DeBerardinis RJ, Amelio AL, Brekken RA, Castrillon DH.

J Clin Invest. 2015 Nov 2;125(11):4063-76. doi: 10.1172/JCI82152. Epub 2015 Sep 28.

46.

Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA.

Cancer Res. 2015 Sep 15;75(18):3699-705. doi: 10.1158/0008-5472.CAN-14-2887-T. Epub 2015 Jul 23.

47.

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B.

Potts MB, McMillan EA, Rosales TI, Kim HS, Ou YH, Toombs JE, Brekken RA, Minden MD, MacMillan JB, White MA.

Nat Chem Biol. 2015 Jun;11(6):401-8. doi: 10.1038/nchembio.1797. Epub 2015 Apr 13.

48.

CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer.

Wei ZW, Xia GK, Wu Y, Chen W, Xiang Z, Schwarz RE, Brekken RA, Awasthi N, He YL, Zhang CH.

Cancer Lett. 2015 Apr 10;359(2):335-43. doi: 10.1016/j.canlet.2015.01.033. Epub 2015 Jan 29.

PMID:
25641338
49.

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.

Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA.

Cell Death Dis. 2015 Jan 15;6:e1599. doi: 10.1038/cddis.2014.564.

50.

Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.

Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE.

Cancer Lett. 2015 Mar 1;358(1):59-66. doi: 10.1016/j.canlet.2014.12.027. Epub 2014 Dec 16.

Supplemental Content

Loading ...
Support Center